Bluebird Bio Inc (NASDAQ:BLUE) Short Interest Increased By 7.07%

May 18, 2018 - By Christine Reyes

bluebird bio, Inc. (NASDAQ:BLUE) Logo

Investors sentiment decreased to 1.51 in 2017 Q4. Its down 0.28, from 1.79 in 2017Q3. It is negative, as 21 investors sold bluebird bio, Inc. shares while 79 reduced holdings. 71 funds opened positions while 80 raised stakes. 50.71 million shares or 3.40% more from 49.05 million shares in 2017Q3 were reported.
Moreover, Point72 Asset Mngmt L P has 0.05% invested in bluebird bio, Inc. (NASDAQ:BLUE). D E Shaw & reported 0.03% in bluebird bio, Inc. (NASDAQ:BLUE). Fairfield Bush And stated it has 2,000 shares or 0.1% of all its holdings. Proshare Advisors Ltd Liability Corporation reported 33,278 shares. Peak6 Investments Ltd Partnership invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Emerald Advisers Inc Pa holds 0.59% or 85,488 shares. 1,200 were reported by Da Davidson And. Pnc Svcs Grp Incorporated reported 0% stake. Glob X Mgmt Ltd Company holds 0% or 273 shares in its portfolio. Chicago Equity Partners Ltd Liability Corporation holds 0.04% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 7,750 shares. Parallax Volatility Advisers Limited Partnership reported 0% stake. Credit Suisse Ag reported 158,806 shares. Moreover, Lord Abbett And Com Limited Liability Com has 0.18% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 357,680 shares. Invesco reported 139,831 shares. State Of Wisconsin Inv Board holds 0.02% in bluebird bio, Inc. (NASDAQ:BLUE) or 44,032 shares.

The stock of Bluebird Bio Inc (NASDAQ:BLUE) registered an increase of 7.07% in short interest. BLUE’s total short interest was 3.77 million shares in May as published by FINRA. Its up 7.07% from 3.52M shares, reported previously. With 471,500 shares average volume, it will take short sellers 8 days to cover their BLUE’s short positions.

The stock increased 6.11% or $10.9 during the last trading session, reaching $189.3. About 865,371 shares traded or 22.10% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 86.28% since May 18, 2017 and is uptrending. It has outperformed by 74.73% the S&P500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $9.49 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 18 analysts covering bluebird bio (NASDAQ:BLUE), 10 have Buy rating, 1 Sell and 7 Hold. Therefore 56% are positive. bluebird bio had 29 analyst reports since November 30, 2017 according to SRatingsIntel. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, May 3. The firm has “Equal-Weight” rating given on Monday, February 26 by Morgan Stanley. Wells Fargo maintained the shares of BLUE in report on Tuesday, December 12 with “Buy” rating. The firm earned “Hold” rating on Monday, May 7 by Bernstein. Jefferies upgraded the stock to “Buy” rating in Monday, December 11 report. As per Wednesday, December 20, the company rating was initiated by Oppenheimer. The firm has “Market Perform” rating by Leerink Swann given on Thursday, January 25. The rating was downgraded by Maxim Group on Wednesday, December 13 to “Hold”. The rating was maintained by Morgan Stanley on Wednesday, March 21 with “Equal-Weight”. The stock has “Buy” rating by Barclays Capital on Wednesday, December 13.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Globenewswire.com which released: “Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive …” on May 15, 2018, also Streetinsider.com with their article: “bluebird bio (BLUE) to Present New Data from LentiGlobin Transfusion-Dependent β-Thalassemia and Severe Sickle …” published on May 17, 2018, Seekingalpha.com published: “Genomic Medicine: Catch The Gene Therapy Wave” on May 14, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Seekingalpha.com and their article: “bluebird bio: Gene Therapy Best In Class” published on May 16, 2018 as well as Nasdaq.com‘s news article titled: “Is bluebird bio One Step Closer to Its First Commercial Drug?” with publication date: April 20, 2018.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: